Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Cluj Napoca – page 13

427 clinical trials in Cluj Napoca, Romania across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Cluj Napoca at a glance
427
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

427 trials in Cluj Napoca

Open in trial search

Study on Niraparib with Immunotherapy for Patients with SLFN11-Positive Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:ETOP IBCSG Partners Foundation

Study of BI-1206 and Pembrolizumab for Patients with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:BioInvent International AB

Still's disease

Recruiting

Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Merck Sharp & Dohme LLC

Hyperkalaemia

Recruiting

Study on the Safety and Effectiveness of Sodium Zirconium Cyclosilicate for Children with High Potassium Levels

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Sodium Zirconium Cyclosilicate
  • Sponsor:AstraZeneca AB

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Astellas Pharma Global Development Inc.

Study on the Effects of Ficlatuzumab and Cetuximab for Adults with Recurrent or Metastatic HPV-Negative Head and Neck Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Aveo Pharmaceuticals Inc.

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Ascentage Pharma Group Inc.

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Mk-1084
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Cluj Napoca

What the registry says about research in the country

01 Cluj Napoca
Oncology and Hematology
The clinical trial landscape in Cluj Napoca is strongly centered on oncology and blood cancers, with studies spanning solid tumors and hematologic malignancies. Major efforts focus on improving treatment effectiveness and long-term outcomes for patients with lung cancer, breast cancer, colorectal cancer, lymphoma, and leukemia. Advanced and early-stage non-small cell lung cancer, including biomarker-driven subtypes Breast cancer, prostate cancer, and bladder cancer studies Lymphoma, multiple myeloma, and leukemia research Trials testing new combinations, targeted therapies, and better post-surgery treatment approaches Many of these studies are designed to refine cancer care by comparing newer therapies with standard treatment and by identifying options for harder-to-treat disease subtypes.
Respiratory and Pulmonary Diseases
There is also a major focus on respiratory medicine, especially chronic and severe lung disease. Research in this area includes trials for COPD, asthma, bronchiectasis, and interstitial lung disease, aiming to improve symptom control and reduce flare-ups. Chronic obstructive pulmonary disease and chronic bronchitis Asthma across mild, moderate, and severe forms Bronchiectasis and interstitial lung disease Studies evaluating better maintenance therapy and new anti-inflammatory approaches These trials reflect a strong interest in helping patients breathe more easily and lowering the burden of long-term lung disease.
Cardiovascular and Kidney Research
Clinical trials in cardiology and nephrology are exploring ways to lower the risk of heart, vascular, and kidney complications. In Cluj Napoca, this includes studies in heart failure, atrial fibrillation, hypertension, stroke prevention, and chronic kidney disease. Heart failure, atrial fibrillation, and atherosclerotic cardiovascular disease Chronic kidney disease and kidney-related complications Hypertension and vascular risk reduction Trials focused on prevention, better control, and fewer cardiovascular events Several studies are aimed at improving long-term outcomes for patients with overlapping heart and kidney conditions.
Gastroenterology, Liver Disease, and Metabolic Disorders
Research in digestive diseases and metabolic health is broad, covering inflammatory bowel disease, liver disease, and metabolic dysfunction. Ongoing trials address ulcerative colitis, Crohn’s disease, NASH, hepatitis B, and diabetes, with a clear emphasis on better disease control and organ protection. Ulcerative colitis and Crohn’s disease Non-alcoholic steatohepatitis and liver fibrosis Type 2 diabetes, obesity, and related metabolic conditions Trials testing new options to improve symptoms, inflammation, and long-term disease outcomes These studies highlight a growing interest in treatments that can ease chronic gastrointestinal symptoms while also addressing broader metabolic risk.
Immunology, Rheumatology, and Autoimmune Disease
A substantial share of research in the city focuses on autoimmune and inflammatory diseases. Trials are studying conditions such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, systemic sclerosis, and Sjögren’s disease, often with the goal of reducing immune-driven damage and improving daily function. Rheumatoid arthritis, psoriatic arthritis, and juvenile psoriatic arthritis Systemic lupus erythematosus, systemic sclerosis, and Sjögren’s disease Plaque psoriasis, atopic dermatitis, and related skin inflammation Studies assessing new immune-targeted treatments for disease control and symptom relief These trials reflect active research into treatments that may better balance immune suppression with safety and long-term benefit.
Neurology and Mental Health
In neurology and psychiatry, trials are examining both chronic neurological disease and mental health conditions. Key areas include multiple sclerosis, epilepsy, migraine, ADHD, major depressive disorder, and schizophrenia. Multiple sclerosis and progressive forms of neurological disease Epilepsy and migraine management ADHD, major depressive disorder, and bipolar disorder Research aimed at improving symptom control, quality of life, and functional outcomes In Cluj Napoca, this area combines brain health research with studies of emotional and behavioral well-being.
Dermatology and Allergy
Skin diseases and allergic disorders are another visible part of the trial portfolio. Research includes atopic dermatitis, alopecia areata, urticaria, bullous pemphigoid, and seasonal allergic rhinitis, with studies designed to ease symptoms and improve skin comfort. Atopic dermatitis and plaque psoriasis Alopecia areata and autoimmune skin conditions Chronic urticaria and allergy-related disorders Trials testing new approaches for inflammation, itch, and visible skin disease These studies often aim to offer better control for conditions that can be both physically uncomfortable and emotionally burdensome.
Infectious Diseases and Immunity
The city’s research activity also includes infectious disease and immunology studies. Trials cover COVID-19, hepatitis B, HIV-1 infection, Clostridioides difficile infection, and other immune-related infections, often with the goal of better prevention or treatment support. Viral infections such as COVID-19, hepatitis B, and HIV Bacterial and fungal infections, including difficult-to-treat cases Immune deficiency and infection-related complications Studies focused on improving infection control and reducing serious complications These trials show continued attention to both common and complex infectious conditions.
Endocrine, Metabolic, and Weight-Related Conditions
Several trials address endocrine and metabolic disorders, reflecting growing interest in diseases linked to hormones, metabolism, and body weight. Research includes type 2 diabetes, acromegaly, thyroid cancer, obesity, and hypertriglyceridemia. Type 2 diabetes and glycemic control Obesity and related metabolic risk Hormonal disorders such as acromegaly Studies evaluating better disease control and reduced long-term complications These projects support a broader effort to improve chronic disease management across metabolism and hormone-related health.
Urology, Nephrology, and Genitourinary Cancers
Research in urinary and reproductive health includes both cancer and non-cancer conditions. Trials focus on prostate cancer, bladder cancer, renal cell carcinoma, benign prostatic hyperplasia, and chronic kidney disease, including studies that may improve treatment precision. Prostate cancer, including advanced and recurrent disease Bladder cancer and kidney cancer Benign prostatic hyperplasia and kidney-related disorders Trials seeking better cancer control and improved urinary tract health These studies are important for patients needing more effective and better-tolerated treatment options.
Rare Diseases, Hematologic Disorders, and Other Specialized Research
Cluj Napoca also supports a wide range of specialized studies in rare diseases and complex blood-related conditions. This includes research in hemophilia, myelofibrosis, thrombocytopenia, amyloidosis, and other uncommon disorders that often need targeted approaches. Hemophilia and thrombocytopenia Myelofibrosis and related marrow disorders Amyloidosis and other rare systemic diseases Studies aimed at finding better symptom control and safer long-term care These trials are especially valuable where treatment choices are limited and specialized expertise is needed.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.